Rosalind Advisors’s Trevi Therapeutics TRVI Stock Holding History

Rosalind Advisors’s Portfolio TRVI Stock Details TRVI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-100,000	Closed	-$1.25M	–	43
2025 Q4	$1.25M	Hold	100,000	–	–	0.44%	29
2025 Q3	$915K	Sell	100,000 -200,000	-67%	-$1.5M	0.31%	31
2025 Q2	$1.64M	Sell	300,000 -312,901	-51%	-$1.95M	0.78%	25
2025 Q1	$3.86M	Sell	612,901 -449,599	-42%	-$2.14M	1.87%	19
2024 Q4	$4.38M	Buy	1,062,500 +312,500	+42%	+$1M	2.24%	17
2024 Q3	$2.5M	Sell	750,000 -641,577	-46%	-$1.91M	1.6%	17
2024 Q2	$4.15M	Buy	1,391,577 +465,561	+50%	+$1.29M	3.19%	14
2024 Q1	$3.19M	Sell	926,016 -936,409	-50%	-$2.09M	2.99%	16
2023 Q4	$2.5M	Buy	+1,862,425	New	+$2.82M	2.06%	19

Other funds holding TRVI

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

Rosalind Advisors's TRVI Position: Q1 2026 in Review

Rosalind Advisors sold out of Trevi Therapeutics (TRVI) in Q1 2026, closing a stake of 100,000 shares — an estimated $1.25M sold.

Rosalind Advisors first reported a position in TRVI in Q4 2023 and held it in 9 quarters. The position peaked at $4.38M in Q4 2024. 198 funds tracked by Wall St. Rank hold TRVI as of Q1 2026.

Rosalind Advisors reported no remaining Trevi Therapeutics position as of Q1 2026 after selling out during the quarter.
Rosalind Advisors sold 100,000 Trevi Therapeutics shares in Q1 2026, an estimated $1.25M.
Rosalind Advisors first reported a position in Trevi Therapeutics in Q4 2023 and held it in 9 quarters.
Rosalind Advisors's Trevi Therapeutics position peaked at $4.38M in Q4 2024.
198 funds tracked by Wall St. Rank held Trevi Therapeutics as of Q1 2026.

Based on Rosalind Advisors's 13F filing for Q1 2026, filed 14 May 2026.